AZD-3161 is a small molecule inhibitor primarily developed for the treatment of cancer, specifically targeting the protein kinase activity of certain receptor tyrosine kinases. It is designed to interfere with signaling pathways that promote tumor growth and survival. The compound exhibits selectivity for specific targets, which is crucial for minimizing off-target effects and enhancing therapeutic efficacy. AZD-3161 has been investigated in preclinical and clinical studies, demonstrating potential in inhibiting tumor proliferation and inducing apoptosis in cancer cells. Its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, are essential for determining the appropriate dosing regimens in clinical settings. Additionally, the compound's safety profile and potential side effects are evaluated during clinical trials to ensure patient well-being. As research continues, AZD-3161 may contribute to personalized cancer therapies, particularly in tumors that exhibit specific molecular characteristics amenable to targeted treatment strategies.

AZD-3161

1369501-46-1: AZD-3161 is a small molecule inhibitor primarily developed for the treatment of cancer, specifically targeting the protein kinase activity of certain receptor tyrosine kinases. It is designed to interfere with signaling pathways that promote tumor growth and survival. The compound exhibits selectivity for specific targets, which is crucial for minimizing off-target effects and enhancing therapeutic efficacy. AZD-3161 has been investigated in preclinical and clinical studies, demonstrating potential in inhibiting tumor proliferation and inducing apoptosis in cancer cells. Its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, are essential for determining the appropriate dosing regimens in clinical settings. Additionally, the compound's safety profile and potential side effects are evaluated during clinical trials to ensure patient well-being. As research continues, AZD-3161 may contribute to personalized cancer therapies, particularly in tumors that exhibit specific molecular characteristics amenable to targeted treatment strategies.

AZD-3161 is a sodium channel regulator for pain.

CAS 1369501-46-1

AZD-3161

AZD-3161

Ref: TM-T30256